<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-id journal-id-type="publisher-id">wox</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization Journal</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3512737</article-id><article-id pub-id-type="doi">10.1097/01.WOX.0000411911.97281.2a</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts of the XXII World Allergy Congress</subject></subj-group><subj-group subj-group-type="heading"><subject>Oral Abstract Session</subject></subj-group><series-title>Rhinitis Treatment 2</series-title></article-categories><title-group><article-title>154&#x02003;A 26-Week Study Evaluating the Safety and Efficacy of Ciclesonide Hydrofluoralkane Nasal Aerosol in Subjects With Perennial Allergic Rhinitis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Berger</surname><given-names>William</given-names></name><degrees>MD, MBA</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohar</surname><given-names>Dale</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Raphael</surname><given-names>Gordon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>LaForce</surname><given-names>Craig</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Holly</given-names></name><degrees>PhD, MPH</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Desai</surname><given-names>Shailesh</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bode</surname><given-names>Frederick</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Karafilidis</surname><given-names>John</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Allergy &#x00026; Asthma Associates, Mission Viejo, CA</aff><aff id="aff2"><label>2</label>Kerrville Research Associates, Kerrville, TX</aff><aff id="aff3"><label>3</label>Asthma, Allergy &#x00026; Clinical Research, Bethesda, MD</aff><aff id="aff4"><label>4</label>North Carolina Clinical Research, Raleigh, NC</aff><aff id="aff5"><label>5</label>Sunovion Pharmaceuticals, Inc., Marlborough, MA.</aff><pub-date pub-type="epub"><day>17</day><month>2</month><year>2012</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2012</year></pub-date><volume>5</volume><issue>Suppl 2</issue><issue-title>Abstracts of the XXII World Allergy Congress, 4&#x02013;8 December, 2012 Canc&#x000fa;n, M&#x000e9;xico</issue-title><fpage seq="b">S68</fpage><lpage>S68</lpage><permissions><copyright-statement>Copyright &#x000a9; 2012 by World Allergy Organization</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="waoj-5-S68a.pdf"/><abstract><sec><title>Background</title><p>Ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) is currently in development as a potential treatment for allergic rhinitis. The objective of this study was to determine the long-term safety and efficacy of CIC-HFA compared to placebo in subjects with perennial allergic rhinitis (PAR).</p></sec><sec><title>Methods</title><p>Subjects &#x02265;12 years of age with a &#x02265;2 year history of PAR were randomized in a placebo-controlled, double-blind, parallel group, multicenter study to CIC-HFA 74 &#x003bc;g (N = 298), CIC-HFA 148 &#x003bc;g (N = 505), or placebo (N = 307) QD AM for 26 weeks. Subject-reported change from baseline in reflective total nasal symptom score (rTNSS) and instantaneous total nasal symptom score (iTNSS) averaged every 2 weeks over the 26 weeks of the treatment period were secondary endpoints and were calculated as a sum of the individual nasal symptoms of congestion, runny nose, sneezing, and nasal itching. Change from baseline in the individual reflective and instantaneous nasal symptom scores averaged every 2 weeks over the 26 weeks of treatment period were also evaluated. Treatment-emergent adverse events (TEAEs) were assessed throughout the study.</p></sec><sec><title>Results</title><p>CIC-HFA 74 &#x003bc;g and CIC-HFA 148 &#x003bc;g doses demonstrated improvement in rTNSS (LS mean change 0.65 &#x00026; 0.52 respectively, <italic>P</italic> &#x02264; 0.01 for both), iTNSS (LS mean change 0.51 &#x00026; 0.42 respectively, <italic>P</italic> &#x02264; 0.05 for both), and improvements in the individual reflective and instantaneous nasal symptoms (<italic>P</italic> &#x02264; 0.05 for all except instantaneous sneezing for the CIC-HFA 74 &#x003bc;g dose) at 26 weeks from baseline. <italic>P</italic>-values were unadjusted for multiplicity. The overall incidence of TEAEs was comparable between the CIC-HFA treatment groups and placebo. The most frequently reported TEAEs (&#x02265;5% of subjects in any treatment group) were headache, nasopharyngitis, upper respiratory tract infections, viral upper respiratory tract infections, sinusitis, and epistaxis.</p></sec><sec><title>Conclusions</title><p>In this study, once-daily treatment with CIC-HFA 74 &#x003bc;g or CIC-HFA 148 &#x003bc;g demonstrated improvements in the nasal symptoms of PAR. Both active treatments were well tolerated.</p></sec></abstract></article-meta></front></article>